Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q1 2015 · 10-Q
Revenue$1.00M$1.00M+7.0% vs Q1 2014 Net Income-$10.17M-$10.17MN/M vs Q1 2014 EPS Diluted-$0.13-$0.13N/M vs Q1 2014 Gross Profit$1,000,287+7.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flow-$9,068,821N/M Free Cash Flowderived-$9,145,828N/M Margins · derivedGross margin100.0%+0.1 pt vs Q1 2014
Operating margin-1350.2%−159.0 pt vs Q1 2014
Net margin-1016.7%−150.5 pt vs Q1 2014
ended Mar 31, 2015 · filed May 8, 2015 · 38 d after period end